Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium) is a clinical research site located in Nashville, Tennessee, United States 37203.
Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium) has participated in 3 clinical trials with 1 currently active.
Therapeutic areas: Non-Small Cell Lung Cancer, Metastatic or Locally Advanced Unresectable Solid Tumors, Non-small Cell Lung Cancer (NSCLC).
Sponsors: Nektar Therapeutics, EMD Serono Research & Development Institute, Inc., Pierre Fabre Medicament.
Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium) has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium) has 3 clinical trials on record, with 1 currently active. Their work covers Non-Small Cell Lung Cancer, Metastatic or Locally Advanced Unresectable Solid Tumors, Non-small Cell Lung Cancer (NSCLC).
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.